高通量筛选鉴定糖原合成酶激酶3α/β为HBV转录所需的宿主因子
研究建立了模拟HBV从转录到病毒出芽的 reporter 基因表达系统,筛选1827种FDA批准化合物,发现GSK3α/β抑制剂(AZD1080、CHIR-98014、CHIR-98021、BIO、AZD2858)可抑制HBV感染原代人肝细胞中HBeAg和HBsAg产生;机制上GSK3α/β磷酸化FOXK1/2,FOXK2 Ser424磷酸化为HBeAg/HBsAg产生所必需。
要点
- GSK3α/β抑制剂在HBV感染原代人肝细胞中抑制HBeAg和HBsAg产生。
- GSK3α/β磷酸化FOXK1/2,FOXK2 Ser424磷酸化为HBeAg/HBsAg产生所必需。
- FOXK2可结合HBV DNA,FOXK2(而非FOXK1)回补恢复HBeAg/HBsAg产生。
核心结论
- 基于重组HBV的筛选系统可发现新靶点,GSK3抑制剂被鉴定为潜在抗HBV药物。
研究设计与样本
- 建立模拟HBV从转录到病毒出芽的HBV报告基因表达系统,筛选1827种FDA批准化合物。
主要发现
- GSK3α/β抑制剂AZD1080、CHIR-98014、CHIR-98021、BIO和AZD2858在HBV感染原代人肝细胞中抑制HBeAg和HBsAg产生。
- 蛋白质组分析显示GSK3α/β磷酸化FOXK1/2。
- HBV感染HepG2-NTCP细胞中FOXK1/2双敲低降低HBeAg和HBsAg产生。
- FOXK1/2双敲低细胞中回补FOXK2而非FOXK1可恢复HBeAg和HBsAg产生。
- FOXK2 Ser424磷酸化为GSK3α/β介导的HBeAg和HBsAg产生所必需;观察到FOXK2与HBV DNA结合。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: HBV leads to severe liver diseases, such as cirrhosis and HCC. Identification of host factors that regulate HBV replication can provide new therapeutic targets. The discovery of sodium taurocholate cotransporting polypeptide (NTCP) as an HBV entry receptor has enabled the establishment of hepatic cell lines for analyzing HBV infection and propagation. Using this new system, studies aimed at identifying host factors that regulate HBV propagation have increased. APPROACH AND RESULTS: We established an HBV-based-reporter gene expression system that mimics HBV replication from transcription to virus egress. Using this approach, we screened 1827 Food and Drug Administration-approved compounds and identified glycogen synthase kinase 3 (GSK3)alpha/beta inhibitors, including AZD1080, CHIR-98014, CHIR-98021, BIO, and AZD2858, as anti-HBV compounds. These compounds suppressed HBeAg and HBsAg production in HBV-infected human primary hepatocytes. Proteome analysis revealed that GSK3alpha/beta phosphorylated forkhead box K1/2 (FOXK1/2)s. A double-knockout of FOXK1/2 in HBV-infected HepG2-NTCP cells reduced HBeAg and HBsAg production. The rescue of FOXK2 expression, but not FOXK1 expression, in FOXK1/2-double-knockout cells restored HBeAg and HBsAg production. Importantly, phosphorylation of FOXK2 at Ser 424 is required for GSK3alpha/beta-mediated HBeAg and HBsAg production. We observed the binding of FOXK2 to HBV DNA in HepG2-NTCP cells. CONCLUSIONS: Our recombinant HBV-based screening system enables the discovery of new targets. Using our approach, we identified GSK3 inhibitors as potential anti-HBV agents.
引用
- Nishitsuji H, Naito Y, Murakami Y, et al. Identification of glycogen synthase kinase 3alpha/beta as a host factor required for HBV transcription using high-throughput screening. Hepatology. 2025. PMID: 39847392. doi:10.1097/HEP.0000000000001239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。